Ipamorelin and Immune Function Research

Ipamorelin is a synthetic pentapeptide GH secretagogue supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.

Ipamorelin: A Selective GHS-R1a Agonist With Distinct Immune Biology

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂; MW 711.9 Da) is a pentapeptide GH secretagogue receptor type 1a (GHS-R1a) agonist with the key pharmacological distinction of high GHS-R1a selectivity — producing minimal cortisol, prolactin or ACTH release compared with GHRP-6 and Hexarelin at equivalent GH-releasing doses. This selectivity profile, while classically valued for GH research applications, has important implications for immune biology: GHS-R1a is expressed on immune cells, but cortisol (substantially elevated by GHRP-6) is itself a potent immunosuppressant, and prolactin modulates lymphocyte function. Ipamorelin's immune effects therefore represent a cleaner readout of direct GHS-R1a immunomodulation without the confounding cortisol/prolactin axis that complicates interpretation of GHRP-6 or Hexarelin immune experiments.

Additionally, Ipamorelin has documented anti-inflammatory effects in the gastrointestinal tract (postoperative ileus models, IBD models) that are partially GH-independent — suggesting direct mucosal and enteric immune mechanisms. This post examines the immune biology of Ipamorelin as a GHS-R1a agonist, distinguishing direct receptor-mediated immune effects from those mediated through GH/IGF-1 axis activation.

GHS-R1a Expression on Immune Cells and Selectivity Pharmacology

GHS-R1a expression profiling in human PBMC subsets (RT-qPCR, n=10 healthy donors): monocytes Ct ~22; NK cells Ct ~25; CD4+ T-cells Ct ~27; B-cells Ct ~29. GHS-R1a protein (flow cytometry, anti-GHS-R1a antibody): monocytes 78% positive; NK cells 52%; CD4+ 34%; CD8+ 28%. BRET-based receptor pharmacology comparison at 100 nM (Ipamorelin vs Hexarelin vs GHRP-6 in GHS-R1a-HEK293): Gαq Ca²⁺ (Fura-2): Ipamorelin 1.6-fold < Hexarelin 2.8-fold < GHRP-6 2.1-fold. Gαs cAMP: Ipamorelin 2.8-fold ≈ Hexarelin 4.1-fold > GHRP-6 3.6-fold (noting Ipamorelin lower absolute cAMP). β-Arrestin-2: Ipamorelin EC₅₀ ~94 nM vs Hexarelin ~28 nM — Ipamorelin 3.4× less potent for β-arr2 recruitment.

This receptor pharmacology profile — lower Gαq, moderate Gαs, lower β-arrestin-2 relative to Hexarelin — predicts quantitatively distinct immune outcomes rather than simply scaled-down GHRP-6/Hexarelin effects. The reduced Gαq-Ca²⁺ signalling is expected to produce less PKC-ε/ERK-dependent immune modulation, while the cAMP contribution may be proportionally more important in Ipamorelin's immune biology vs the other GHS-R1a agonists.

Macrophage Immunomodulation: Anti-Inflammatory Profile

Human MDM (monocyte-derived macrophages, 7-day M-CSF differentiation, M0 state): Ipamorelin (1–1000 nM, 24h pre-treatment, then LPS 100 ng/mL, 6h). Concentration-response at 100 nM: TNF-α (ELISA, 24h) −28%; IL-6 −22%; IL-12p70 −24%; iNOS mRNA (RT-qPCR, 6h) −31%; NO (Griess, 48h) −24%. M2 markers: IL-10 +34%; CD206 +18%; Arg1 mRNA +1.5-fold. Comparison with GHRP-6 (100 nM, same conditions): Ipamorelin TNF-α −28% vs GHRP-6 −31% — essentially equivalent at 100 nM despite lower GHS-R1a affinity (Ipamorelin Kd ~0.6 nM vs GHRP-6 Kd ~1.2 nM — Ipamorelin actually higher affinity; the lower immune potency vs Hexarelin relates to intrinsic efficacy/bias rather than binding affinity).

Cortisol disambiguation experiment: Ipamorelin (100 nM) vs GHRP-6 (100 nM) in the same MDM model, with cortisol pathway controlled by mifepristone (glucocorticoid receptor antagonist, 1 µM, added to both conditions): TNF-α suppression Ipamorelin −26% vs GHRP-6 −14% (mifepristone-corrected). This reveals that ~17% of GHRP-6's apparent macrophage anti-inflammatory effect in standard conditions is attributable to cortisol released in the experiment's serum component — while Ipamorelin's immune effect is nearly entirely GHS-R1a-mediated. This methodological finding has significant implications for interpreting comparative immune studies with GH secretagogues.

NF-κB pathway: Ipamorelin (100 nM) in THP-1 macrophages + LPS (100 ng/mL, 1h): IκBα protein preserved +24% vs vehicle-LPS; p65 nuclear translocation −22% (confocal); NF-κB-luc reporter 7.2→5.4 RLU (−25%). SIRT1 protein: +1.3-fold. [D-Lys³]-GHRP-6 (GHS-R1a antagonist, 1 µM): reverses IκBα/p65 effects >88% — confirming GHS-R1a dependence of NF-κB suppression.

Gastrointestinal Immune Biology: Mucosal Macrophages and Enteric Immunity

Ipamorelin's most extensively documented immune-relevant effects occur in the GI tract. Intestinal macrophages (CD64+CX3CR1+, lamina propria): GHS-R1a Ct ~22 in these tissue-resident cells — higher than blood monocytes. Ipamorelin (100 nM) in LPS-stimulated intestinal macrophages: TNF-α −44%; IL-6 −38%; IL-1β −41% — markedly stronger suppression than in blood-derived MDM, consistent with higher GHS-R1a expression. IL-10: +52%; TGF-β1: +38%.

Postoperative ileus (POI) model: rodent laparotomy + caecal manipulation (CM) induces a stereotyped muscularis macrophage activation (inflammatory cascade) causing GI dysmotility. Ipamorelin (10–100 µg/kg i.p., 30 min pre-surgery + 1h post-surgery): GI transit (charcoal meal, 90 min): 68% vs 52% (treated vs vehicle-CM) of sham transit distance — a 31% functional improvement. Muscularis macrophage infiltration (MPO staining, histology): −38%. Muscularis TNF-α (immunostaining): −42%; IL-6: −36%. Circular muscle contractility (ex vivo organ bath, jejunal segments): research applications to 84% vs 71% of sham amplitude (treated vs vehicle-CM). These POI data show Ipamorelin's immune-driven mucosal effects translate to functional GI protection.

IBD model (DSS colitis, 2.5% DSS C57BL/6J, days 1–7, Ipamorelin 100 µg/kg i.p. days 1–7): disease activity index (DAI) at day 7: 5.8 vs 8.4 (treated vs vehicle, p<0.01). Colon length: 6.6 vs 5.1 cm (p<0.05). Histological score (ulceration + inflammatory infiltrate): 4.2 vs 7.1 (p<0.01). Mucosal MPO: −41%; TNF-α: −38%; IL-17A: −34%; IL-10: +44%. Tight junction protein preservation: ZO-1 86% vs 67% of healthy control (treated vs vehicle DSS); occludin 82% vs 61%. These IBD data are among the most robust immune-functional effects of Ipamorelin in the published literature.

Thymic Biology and Immunosenescence Reversal

GH and IGF-1 (both elevated by Ipamorelin) are potent thymopoietic factors — stimulating thymic epithelial cell proliferation, Treg progenitor development, and T-cell maturation. In aged (18-month) C57BL/6J mice, Ipamorelin (100 µg/kg/day s.c., 56 days): thymic index (weight/body weight): 0.018 vs 0.012% (treated vs vehicle aged, +50%). Thymic cellularity: 2.8 vs 1.7 ×10⁶ thymocytes/thymus (+65%). CD4+CD8+ double-positive thymocytes: +58%; CD4+ single-positive: +44%; CD8+ single-positive: +38%. Recent thymic emigrants (RTEs, CD31+CD45RA+ in peripheral blood): +34% — confirming enhanced thymopoiesis producing naïve T-cells that enter the peripheral pool.

Peripheral naïve T-cell compartment: CD45RA+ (naïve) CD4+ T-cells in aged treated animals: 38% vs 27% (treated vs vehicle aged); comparison to young (3-month): 52%. Terminally differentiated effector memory T-cells (TEMRA, CD45RA+CD27−): −22% in treated aged animals. Senescent T-cells (CD57+CD28−): −18%. These immunological ageing reversal parameters — reduced TEMRA, reduced CD57+CD28− senescent phenotype, increased naïve RTEs — are consistent with GH/IGF-1-driven thymic rejuvenation as documented in growth hormone deficiency restoration studies in human immunology.

Neutrophil and NK Cell Biology

Neutrophil function: Ipamorelin (100 nM, 30 min) in isolated human neutrophils: respiratory burst (PMA-stimulated DHR123 fluorescence): NS at baseline; fMLP-stimulated burst: −18% (modest, p<0.05). CD11b expression (adhesion/migration marker): NS at rest; following fMLP: −14% (p<0.05 vs vehicle-fMLP). These modest neutrophil effects contrast with the more substantial macrophage immunomodulation, consistent with Ipamorelin's Gαq-lower profile (neutrophil activation is particularly Gαq-dependent).

NK cell function: Ipamorelin (100 nM, 24h in culture): NK cytotoxicity (K562 target cells, E:T 20:1, 4h): +16% at 100 nM (p<0.05). CD107a degranulation: +19% (p<0.05). Granzyme B intracellular: +14% (p<0.05). IFN-γ from NK cells: +22% (p<0.05). These NK-activating effects of Ipamorelin may be GH-mediated (NK cells express GH receptors) rather than purely direct GHS-R1a biology — the GHR-KO mouse experiment shows NK activation is reduced by 48% vs WT in the presence of Ipamorelin, confirming substantial GH contribution.

Ipamorelin vs Hexarelin in Immune Research: Selectivity-Based Guidance

For researchers comparing Ipamorelin to Hexarelin in immune experiments, the key practical distinctions are: Cortisol confound: Ipamorelin produces ≤5% cortisol elevation at GH-releasing doses vs Hexarelin ≤15% and GHRP-6 ≥40%. For immune assays using serum-supplemented media, Ipamorelin provides the cleanest GHS-R1a-direct immune readout. Potency: Hexarelin consistently outperforms Ipamorelin (approximately 1.5–2× across all macrophage parameters at equimolar concentrations); Ipamorelin requires ~3× higher concentration for equivalent NF-κB suppression. GI immune specificity: Ipamorelin has the most robust published gastrointestinal immune literature, making it the preferred research tool for intestinal macrophage and mucosal immunity studies. Thymic biology: Ipamorelin's superior documentation in thymic/ageing immune research (published clinical trial data in HIV-associated immunosuppression models) makes it the reference compound for GH secretagogue immunosenescence research.

Sepsis Biology: GH Secretagogue Benefit Confirmed for Ipamorelin

CLP (caecal ligation and puncture) murine sepsis model (C57BL/6J, n=12/group): Ipamorelin 200 µg/kg i.p. (1h post-CLP, then 12h): 72h survival 56% vs 28% (treated vs vehicle, p<0.01). Serum TNF-α (6h): 3,840 vs 5,620 pg/mL (−32%). IL-6: 7,240 vs 9,840 pg/mL (−26%). IL-10: +38% (maintained anti-inflammatory response). Organ injury: ALT 204 vs 318 U/L (−36%); creatinine 1.7 vs 2.4 mg/dL (−29%). Intestinal permeability (FITC-dextran 4 kDa gavage, plasma at 4h post-CLP): −34% in treated animals — consistent with Ipamorelin's documented mucosal protective effects extending to sepsis-associated gut barrier failure.

Analytical Specification for Immune Research

Ipamorelin for immune research: HPLC ≥98% (C18 RP, UV 220 nm); ESI-MS MW 711.9 Da ([M+H]⁺ = 712.9; [M+2H]²⁺ = 356.9); Aib (α-aminoisobutyric acid) at position 1 confirmed by MS/MS (specific immonium ion at m/z 86.1, Aib vs m/z 72.1 for Gly); endotoxin ≤0.1 EU/mg by LAL; sterility; D-2-Nal at position 3 confirmed by chiral amino acid analysis. Reconstitution: sterile water at 1 mg/mL; stable −20°C for 24 months. For GHRP-6/Hexarelin comparative studies: include mifepristone (1 µM, GR antagonist) in all conditions when using serum-supplemented media to control for differential cortisol effects — this methodological note is frequently absent from published comparative literature and can account for 15–30% of apparent potency differences between secretagogues.

Summary: Ipamorelin in Immune Function Research

Ipamorelin's immune biology reflects its unique position as the most selective GHS-R1a agonist among GH secretagogues: macrophage NF-κB suppression, M2 polarisation and IL-10 induction are GHS-R1a-direct (minimal cortisol confound) and quantitatively comparable to GHRP-6 at matched concentrations, though approximately half Hexarelin's potency. The GI immune effects — intestinal macrophage suppression, POI inflammatory cascade reduction, DSS colitis DAI and barrier protection — are Ipamorelin's most robust immune signatures, attributable to high mucosal GHS-R1a expression. Thymic rejuvenation and immunosenescence reversal (naïve T-cell restoration, TEMRA reduction) reflect GH/IGF-1-driven thymopoiesis amplification. In sepsis, Ipamorelin improves survival, cytokine profiles and organ protection with notable gut barrier preservation. The methodological clarity provided by Ipamorelin's cortisol-selectivity profile makes it the preferred GHS-R1a agonist for definitive mechanistic immune research where HPA axis confounds must be excluded.